NEWTON, Mass. — Manifold announced it has raised $18 million in a Series B financing round to accelerate development of its vertical AI platform for life sciences and expand adoption across the biopharma and healthcare ecosystem.
The round was led by Reach Capital, with participation from SilverArc Capital, Industry Ventures, and existing investors TQ Ventures and Calibrate Ventures. The funding brings Manifold’s total capital raised to $40 million.
Manifold said the new capital will support continued expansion of its AI-driven platform, which is designed to help life sciences organizations accelerate workflows spanning early discovery, clinical development, market access, and precision medicine. The company positions its technology as a purpose-built alternative to horizontal AI platforms, designed to handle the complexity of biomedical data, regulated environments, and multi-organization collaboration.
“In every industry, companies that combine agentic AI and domain-specific context will transform productivity. Customers are seeking proven partners in this transformation. We believe Manifold is the emerging category leader for vertical AI in life sciences,” said Jennifer Carolan, Partner at Reach Capital.
The company said the funding will be used to expand its Agent OS, enabling AI agents to work more effectively with multimodal biomedical data, scientific tools, and institutional context across use cases such as biomarker development, model validation, trial design, and real-world evidence generation. Manifold also plans to deepen collaboration features that allow teams to share analyses and work across organizational boundaries while maintaining data governance and ownership.
In addition, Manifold said it will continue scaling its data ecosystem, allowing organizations to construct and contribute novel datasets that increase platform value while preserving data sovereignty.
Over the past year, Manifold reported increased momentum across product development and customer adoption. The company said its AI agents are now used across dozens of workflows, including cohort identification, biomarker discovery, treatment pathway analysis, and outcomes research. Its customer base includes biopharma companies and academic medical centers, including Foundation Medicine and the University of Virginia.
Manifold has also expanded strategic collaborations with organizations including the Broad Institute, AWS, and Anthropic, and now operates Terra, serving thousands of researchers across hundreds of life sciences organizations worldwide.
“Our customers and partners are pushing the boundaries of what’s possible in life sciences, and we’re honored to build alongside them. This funding accelerates our shared goal to transform productivity in life sciences and get life-changing medicines to patients faster,” said Vinay Seth Mohta, CEO of Manifold.
